Impact of patient’s health-related quality of life on physicians’ therapy and perceived benefit in acute coronary syndromes: protocol for a systematic review of quantitative and qualitative studies

Billingsley Kaambwa,1 Hailay Gesesew,2,3 Matthew Horsfall,4 Derek P Chew5

ABSTRACT

Introduction Percutaneous coronary interventions (PCIs) and coronary angiography are two of the treatments administered to acute coronary syndrome (ACS) patients. However, whether and how patients’ health-related quality of life (HRQoL) influences treatment decisions and subsequent risk benefit analyses is unclear. In this study, we will review the available evidence on the impact of patients’ HRQoL on physicians’ prescribing or treatment decisions and on the estimation of mortality and bleeding risk in ACS patients.

Methods and analysis We will undertake a systematic review of all quantitative and qualitative studies. The search will include studies that describe the impact of HRQoL on prescribing PCIs or angiography, and impact of HRQoL on perceived risks in terms of mortality and bleeding events. We will conduct an initial search on Google scholar and MEDLINE to build the searching terms followed by a full search strategy using all identified keywords and index terms across the five databases, namely MEDLINE, PubMed, CINAHL, SCOPUS and Web of Sciences. We will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for protocol guidelines to present the protocol. Only English language articles will be included for the review. We will use a standardised Joanna Briggs Institute data extraction tool to synthesise the information extracted from the selected studies into themes with summary findings presented in a table.

Ethics and dissemination We will not require a formal ethical approval as we will not be collecting primary data. Review findings will be disseminated through a peer-reviewed publication, workshops, conference presentations and a media release.

INTRODUCTION

Acute coronary syndrome (ACS) is one of the most common set of conditions that patients in emergency departments present with and which often leads to hospitalisation.1 It is characterised by a number of clinical symptoms including unstable angina, non-ST-segment elevation myocardial infarction (MI) and ST-segment elevation MI.1 The definitions of ACS depend on multiple range of activities including history taking, physical examination and reviews of electrocardiography, chest radiograph and cardiac biomarker test results.1 Evidence from the literature shows that risk stratification is an essential prerequisite to decision-making, particularly when determining whether (1) patients will be treated in a coronary care unit or monitored step-down unit, (2) treatment will be invasive or non-invasive or (3) prognosis will be good or bad.2,4 For the interest of this review, we will use either of the ACS diagnosis described by the authors in the primary study in order to include as many studies as possible.

Physicians have developed a number of multivariable risk assessment methods to help them provide a comprehensive assessment of risk and an accurate method of prognosis for patients with ACS.5 These methods thereafter inform the treatment choice based on strategies that include percutaneous coronary intervention (PCI) and coronary
angiography.\(^6\)\(^7\) Despite the existence of these risk assessment techniques, however, physicians still use their clinical intuition to prescribe therapies and estimate potential benefit and harm.\(^8\)\(^9\) Whether, and the extent to which, patients' health-related quality of life (HRQoL) influences this treatment choice is unclear in the literature. To date, HRQoL has several measurements with different scales, number of items, scoring calculation and interpretation. For example, Short Form 6, 12 and 36 dimension (SF-6D, SF-12 and SF-36),\(^10\)\(^11\)\(^12\) Seattle Angina Questionnaire (SAQ),\(^13\)\(^14\) Duke Activity Status Index (DASI),\(^15\) Nottingham Health Profile (NHP)\(^16\)\(^17\) and the Euro-Qol 5 dimensions three-level or five-level measures were some of the validated tools used to measure HRQoL. In this review, no a priori definition is specified in order to be more inclusive of a broad range of literature.

Few studies report on what factors influence physicians' decision-making in terms of treatment and risk assessment for ACS patients. For example, some studies report that being in high-risk clinical subgroups such as old age, male gender as well as having diabetes, renal failure, other cardiac comorbidities or a previous history of ACS are significant factors that influence this decision-making.\(^8\)\(^18\)\(^19\) Unfortunately, these group of patients are also at high risk of increased adverse outcomes of ACS management.\(^20\) However, evidence of the impact of HRQoL on decision-making and risk assessment is lacking. 'Impact' in this review is referred to a situation where treatment risk estimation was modified or altered as a result of HRQoL.

A review in the USA\(^21\) found that that several patients with ACS consider HRQoL while deciding to choose a treatment strategy although the survival benefit is similar among the available therapies. In particular, the review noticed that there were variations in preferences over the duration of HRQoL. Some patients chose easy treatment strategy that brings favourable HRQoL for short duration—for instance, patients chose PCI instead of CAGB. To the contrary, other patients chose a complex treatment strategy to have a favourable QoL for longer period of time—for instance, patients chose CAGB instead of PCI. Most patients understood less these existing trade-offs. It is against this impact that the review recommended that physicians should have to consider advising their patients about the HRQoL benefit before deciding to choose a treatment strategy. Thus, there will be a need to consider provide objective information on HRQoL by physicians. Furthermore, the literature review revealed that clinical trials, treatment guidelines and polices should have to consider HRQoL while deciding to prescribe among treatment strategies.

Several definitions have been used to measure bleeding in hospital and post-discharge periods, including Bleeding Academic Research Consortium (BARC). Although evidence on the relationship between bleeding event and QoL is scarce, the existing evidence demonstrated worse QoL following a bleeding event.\(^22\)\(^23\) For example, Amin \textit{et al} found a 24% prevalence of bleeding among patients with ACS undergoing PCI, and the 6-month QoL was worse.\(^22\) Furthermore, evidence show the association between change in QoL and mortality.\(^24\)\(^25\) Nevertheless, the degree to which this HRQoL affects the estimation of the risk of mortality or bleeding events in patients with ACS is uncertain.\(^8\)\(^26\)\(^27\)

Therefore, this study will review the available evidence on HRQoL and other factors affecting physicians' therapy decisions and their assessment of risk for ACS patients. In particular we will review, (1) the status of HRQoL in patients with ACS before and after treatment, (2) the impact of HRQoL on physician’s treatment decision in ACS patients and (3) the impact of patient’s HRQoL on physician’s estimation of the potential outcomes such as mortality and bleeding risk.

**METHODS AND DESIGN**

**Population**

The systematic review will include studies on physicians who screen and diagnose patients with ACS and prescribe PCI or angiography therapy.

**Study design**

The systematic review will consider quantitative and qualitative studies of good quality published before June 2018.

**Search strategy**

We will perform the following steps to undertake the searching strategy. First, we will carry out a limited search through Google scholar and MEDLINE in order to develop key terms for the three pre-defined concepts relating to the research question: concept 1 (predictors, factors, quality of life or life quality), concept 2 (physician therapy, percutaneous coronary intervention, percutaneous transluminal angioplasty, PTA, PTCA, PCI, angiography, revascularisation, bleeding events, mortality, death, clinical intuition, perceived benefit, perceived risk, risk stratification, estimated benefit or estimated risk) and concept 3 (ACS, coronary heart disease, MI or heart infarction). Second, we will carry out a full search (online supplementary annex 1) using all identified keywords and index terms across the following databases: MEDLINE, PubMed, CINAHL, SCOPUS and Web of Sciences. Concepts 1, 2 and 3 will be connected by ‘AND’ to run the full searching strategy in the aforementioned databases. Next, titles and abstracts from each database will be screened and relevant titles/abstracts selected for a full text appraisal. Finally, we will undertake backward and forward citation chaining of relevant documents. The search will also include unpublished studies or grey literature from ProQuest Dissertations and Theses (PQDT), WHO, Health department Data and other health data repositories.

Figure 1 describes the schematic presentation of the search strategy using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Prior to inclusion in the review, two primary but independent reviewers, HAG and BK, will assess the selected papers for methodological validity using a standardised Joanna Briggs Institute (JBI) appraisal instruments28 (online supplementary annex 2). Any disagreement will be resolved by consensus among the research team.

Quality assessment
The two primary reviewers will independently assess the methodological quality of the included studies using an appraisal form developed by the JBI (online supplementary annex 2). In addition, we will assess the risk of bias via the Agency for Healthcare Research and Quality (AHRQ) criteria.29

Data extraction
Quantitative and qualitative data will be extracted from papers based on the JBI data extraction tool (online supplementary annex 3). We will extract relevant information from all articles included in the review into a spreadsheet. Whenever, there is missing or unclear data, we will contact authors of primary studies. Both primary reviewers will independently check the data extraction.

Outcomes
The review will consider the following physician outcomes:

► Prescription of PCI for patients with ACS.
► Prescription of angiography for ACS patients.
► Estimation of mortality risk to ACS patients.
► Estimation of bleeding events for ACS patients.

Definitions and measurements of estimated (perceived) mortality and bleeding events benefit are described elsewhere.8 Briefly, bleeding events were measured using Thrombolysis in Myocardial Infarction (TIMI), Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) and the ACUTY bleeding criteria.

Exposures
The primary exposure in this review will be HRQoL as defined by a number of HRQoL instruments. These will include the Short Form 6, 12 and 36 dimensions (SF-6D, SF-12 and SF-36, respectively).10–12 SAQ,13 14 DASI15 NHP16 17 and the Euro-Qol 5 dimensions three- or five-level measures (EQ-5D-3L or EQ-5D-5L). The secondary exposures or confounders will include age, sex, diabetes mellitus, renal failure, smoking, family history of cardiac illnesses, presenting with cardiac shock or cardiac arrest, other cardiac comorbidities and previous history of ACS.

ANALYSIS
A narrative synthesis of outcomes along with the exposure variable of selected studies will be demonstrated in the final review. We will include the following information to summarise the main data from the included studies: author (year), setting, study design, population, sample size, outcome and main findings. The factors for both outcomes, physicians’ treatment decision and assessment of perceived risk, will be summarised into themes, and summary findings of each study included in the review will be presented in tables.

If data will be available, meta-regression and meta-analyses will be conducted to see the association of the factors with the aforementioned outcomes. We will assess the clinical and statistical heterogeneity before conducting the meta-analyses. The research team will check the clinical heterogeneity to decide which variable and outcome will be added in the meta-analysis. We will use standard Chi-square and I² tests to diagnose the statistical heterogeneity, with significant heterogeneity detected at the p<0.05. In addition, meta-analyses will be carried out separately for each outcome and each exposure of interest using RevMan-5 Software.30 We will consider meta-analysis if I² will be below 85%.31 In order to calculate effect sizes, we will use a Mantel Haenszel statistical method with forest plots used to graphically depict the relationship between exposures of interest and outcomes or events.

Based on the degree of statistical heterogeneity, we will calculate a pooled unadjusted OR estimates and their 95% CIs using random or fixed effect meta-analysis.31 If the outcome is reported using continuous data, we will use a mean difference (MD) or standardised mean difference (SMD). MD will be used if all included studies use the same scale whereas SMD will be used if the included studies applied variety scales. If the number of studies that reported the exposure and outcome of interest will be small (n<5), we will only consider fixed effect model irrespective of the level of heterogeneity.32 34 We will consider pooling if at least two studies assess the outcomes and the exposures of interest. To assess the publication bias, we
will use a funnel plot. We will also consider a sensitivity test via omitting and entering small studies and deviant results from the rest of the studies (outliers). The strength of the body of evidence will be assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE).

Ethics and dissemination
This study will not require a formal ethical approval because it will not involve collection of primary data. To disseminate findings of the Review, we will use the following media: publishing in peer-reviewed journals, presenting on workshops, conference and sharing through a media release.

Patient and public involvement
No patient or public is involved as this is a review of studies.

CONCLUSION
This systematic review will provide evidence in support of, or against, the hypothesis that patients’ HRQoL has a role in physicians’ treatment decisions and in estimating the mortality and bleeding event risk for ACS patients. Particularly, this review will assess the impact that HRQoL, measured using validated instruments, has on prescribing PCI and angiography. Furthermore, the role of HRQoL on estimating mortality and bleeding events benefit will also be enumerated. We will apply descriptive and inferential statistical analysis to summarise the quantitative data from the review and synthesise the qualitative component of the findings into themes. In general, the review will contribute to the clinical evidence base on what drives clinical intuition during the treatment decision-making for ACS patients.

Author affiliations
1Health Economics, Flinders University Faculty of Medicine Nursing and Health Sciences, Adelaide, South Australia, Australia
2Epidemiology, Institute of Health Jimma University, Jimma, Oromia, Ethiopia
3Public Health, Flinders University, Adelaide, South Australia, Australia
4South Australian Health and Medical Research Institute, SAHMRI, Adelaide, South Australia, Australia
5Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia

Acknowledgements
We thank Flinders University for enabling us to access not freely available articles. We also acknowledge authors of primary studies.

Contributors
BK and HG contributed equally to this paper. DPC, BK and HG conceived the idea. BK and HG drafted the protocol. All authors contributed to the development of the selection criteria, the risk of bias assessment strategy and data extraction criteria. BK and HG developed the search strategy. DPC and MH provided expertise on estimating mortality and bleeding events benefit will also be enumerated. We will apply descriptive and inferential statistical analysis to summarise the quantitative data from the review and synthesise the qualitative component of the findings into themes. In general, the review will contribute to the clinical evidence base on what drives clinical intuition during the treatment decision-making for ACS patients.

REFERENCES
1. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc 2009;84:917–38.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148–304.
3. Falk V, Baumgartner H, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2017;52:616–64.
4. Marechais S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis. Eur Heart J 2010;31:1390–7.
5. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727–33.
6. Henninges JP, Claessen BE, Dangas GD, et al. Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention—From the PROTECT II randomized trial. Int J Cardiovasc 2015;189:272–8.
7. Kirtane AJ, Doshi DJ, Lemos PA, et al. Dual-Eligibility Enrollment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention. Circulation 2016;134:422–31.
8. Chew DP, Juergens C, French J, et al. An examination of clinical intuition in risk assessment among acute coronary syndrome patients: observations from a prospective multi-center international observational registry. Int J Cardiol 2014;171:209–16.
9. Yan AT, Yan RT, Huyhn T, et al. Understanding physicians’ risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry. Arch Intern Med 2006;166:372–8.
10. van Domburg RT, Daemen J, Morice MC, et al. Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II: sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention 2010;5:362–7.
11. Favaro ME, Hueb W, Boden WE, et al. Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. Int J Cardiol 2007;116:364–70.
12. Thiele H, Neumann-Schneidewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009;53:2324–31.
13. Borkont AM, Muehlebach GF, House J, et al. A comparison of the recovery of health status after percutaneous coronary intervention and coronary artery bypass. Ann Thorac Surg 2002;74:1526–30. discussion 30.
14. Zhang Z, Mahoney EM, Stables RH, et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation 2003;108:1694–700.
15. Hlatky MA, Boothroyd DB, Melpos KA, et al. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation 2004;110:1960–6.
16. Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation 1996;94:135–42.
17. Währborg P. Quality of life after coronary angioplasty or bypass surgery. 1-year follow-up in the Coronary Angioplasty versus Bypass Revascularization investigation (CABRI) trial. *Eur Heart J* 1999;20:653–8.

18. Hung J, Briejer DB, Amerena JV, et al. Treatment disparities and effect on late mortality in patients with diabetes presenting with acute myocardial infarction: observations from the ACACIA registry. *Med J Aust* 2009;191:539–43.

19. Jneid H, Fonarow GC, Cannon CP, et al. Sex differences in medical care and early death after acute myocardial infarction. *Circulation* 2008;118:2803–10.

20. Dai X, Busby-Whitehead J, Alexander KP. Acute coronary syndrome in the older adults. *J Geriatr Cardiol* 2016;13:101–8.

21. Blankenship JC, Marshall JJ, Pinto DS, et al. Effect of percutaneous coronary intervention on quality of life: a consensus statement from the Society for Cardiovascular Angiography and Interventions. *Catheter Cardiovasc Interv* 2013;81:243–59.

22. Amin AP, Wang TY, McCoy L, et al. Impact of Bleeding on Quality of Life in Patients on DAPT: Insights From TRANSLATE-ACS. *J Am Coll Cardiol* 2016;67:59–65.

23. Doble B, Pufulete M, Harris JM, et al. Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study. *Health Qual Life Outcomes* 2018;16:191–91.

24. Perl J, Karaboyas A, Morgenstern H, et al. Association between changes in quality of life and mortality in hemodialysis patients: results from the DOPPS. *Nephrol Dial Transplant* 2017;32:521–7.

25. Lieberman S, Li NC, Lacson E. Change in quality of life and one-year mortality risk in maintenance dialysis patients. *Qual Life Res* 2016;25:2295–306.

26. Fox KA, Anderson FA, Dabbous OH, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). *Heart* 2007;93:177–82.

27. Scott IA, Derhy PH, O’Kane D, et al. Discordance between level of risk and intensity of evidence-based treatment in patients with acute coronary syndromes. *Med J Aust* 2007;187:153–9.

28. Joanna Briggs Institute (JBI). Joanna Briggs Institute reviewers’ manual. Adelaide, SA: JBI, 2014.

29. Viswanathan M, Ansari MT, Berkman ND, et al. AHRQ Methods for Effective Health Care: Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Rockville (MD): Agency for Healthcare Research and Quality, 2008:14.

30. *Review Manager (RevMan) [Computer program] [program]. 5.3 version. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.*

31. L-b J, Viv R. Presenting and interpreting meta-analyses: Heterogeneity School of Nursing and Academic Division of Midwifery, University of Nottingham. 2007 http://www.nottingham.ac.uk/sonet/ros/ebp/meta-analysis2/4.html (accessed 02 May 2016).

32. Sen S. Odds ratios revisited. *Evidence-Based Med* 1998;3.

33. Borenstein M, Hedges L, Rothstein H. Meta-analysis: fixed effect vs. random effects, 2007 https://www.meta-analysis.com/downloads/Meta-analysis%20fixed%20effect%20vs%20random%20effects.pdf (accessed 17 May 2016).

34. Tufanaru C, Munn Z, Stephenson M, et al. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. *Int J Evid Based Healthc* 2015;13:196–207.